Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients

被引:22
作者
Hoshida, Y
Hongyo, T
Nakatsuka, S
Nishiu, M
Takakuwa, T
Tomita, Y
Nomura, T
Aozasa, K
机构
[1] Osaka Univ, Sch Med, Dept Pathol C3, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Sch Med, Dept Radiat Biol, Suita, Osaka 5650871, Japan
关键词
D O I
10.1038/labinvest.3780419
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Post-transplantation lymphoproliferative disorder (PT-LPD) is characterized by lymphoid proliferation after organ or bone marrow transplantation. In Western countries, most cases of PT-LPD are B-cell-derived and Epstein-Barr virus-associated, in which alterations of c-myc, p53, and N-ras genes might play a role in disease progression. In Japan, PT-LPD of T- and NK/T-cell types are not uncommon in renal transplant patients. Mutations of p53 (exons 4 through 8), K-ras (exons 1 and 2), c-kit (exons 11 and 17), and beta-catenin genes (exon 3) in 12 cases of these diseases were analyzed by PCR single strand conformation polymorphism and then by direct sequencing. p53 gene mutations were detected in 5 of 5 cases of peripheral T-cell lymphoma, 3 (60%) of 5 cases of adult T-cell leukemia/lymphoma, and 1 of 2 cases of NK/T cell lymphoma. Twenty-five percent of T and NK/T cell lymphomas showed K-ras mutations. Mutations of c-kit and beta-catenin genes were found in 33% of cases. Among a total of 42 substitution mutations, 40 were transitions with involvement of CpG sites in 20 to 30% of cases. Most cases had at least one mutation that changed an amino acid, which might have provided the selection pressure for expansion. These findings suggested that p53 gene mutations might play a central role in development of peripheral T-cell lymphoma including adult T-cell leukemia/lymphoma in renal transplant patients.
引用
收藏
页码:257 / 264
页数:8
相关论文
共 40 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   P53 MUTATION AND EXPRESSION IN LYMPHOMA [J].
ADAMSON, DJA ;
THOMPSON, WD ;
DAWSON, AA ;
BENNETT, B ;
HAITES, NE .
BRITISH JOURNAL OF CANCER, 1995, 72 (01) :150-154
[3]  
ARAKAWA K, 1990, TRANSPLANTATION, V49, P213
[4]  
BALLERINI P, 1993, BLOOD, V81, P166
[5]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[6]   Functional interaction of beta-catenin with the transcription factor LEF-1 [J].
Behrens, J ;
vonKries, JP ;
Kuhl, M ;
Bruhn, L ;
Wedlich, D ;
Grosschedl, R ;
Birchmeier, W .
NATURE, 1996, 382 (6592) :638-642
[7]  
BRENTNALL TA, 1995, CANCER RES, V55, P4264
[8]  
Chadburn A, 1998, CANCER, V82, P1978
[9]   Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients [J].
Dockrell, DH ;
Strickler, JG ;
Paya, CV .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :180-182
[10]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221